Roy S. Herbst was named the inaugural deputy director for clinical affairs at Yale Cancer Center and Smilow Cancer Hospital. The appointment is effective immediately and is in addition to Herbst’s role as chief of the Section of Medical Oncology and associate cancer center director for translational research at Yale Cancer Center.
Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
